CRISPR Therapeutics CRSP Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from CRISPR Therapeutics’s reported figures.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's free cash flow?
- CRISPR Therapeutics (CRSP) reported free cash flow of -$109.4M in Q1 2026.
- How has CRISPR Therapeutics's free cash flow changed year-over-year?
- CRISPR Therapeutics's free cash flow decreased by 102.0% year-over-year, from -$54.15M to -$109.4M.
- What is the long-term trend for CRISPR Therapeutics's free cash flow?
- Over 3 years (2022 to 2025), CRISPR Therapeutics's free cash flow has grown at a -13.4% compound annual growth rate (CAGR), from -$532.93M to -$345.93M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.